Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
for Chronic Graft-versus-host Disease (cGVHD)
Drug: Ruxolitinib
Sites in Philadelphia +5 more locations
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sex: All·Age: 18+
Code: NCT06660355·Phase 2·Recruiting·Listed Oct 2024